Riskpilot← Back to searchSign inGet full accessFISHER SCIENTIFIC AS
ASActiveOrg 940354137Ullernchausséen 52, 0379 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 198612 employees
Revenue 2024
NOK 116,2M
+5% vs 2023
EBITDA margin
1.8%
-32% vs 2023
Equity ratio
61.6%
Financial strength
Net profit 2024
NOK 2,3M
-14% vs 2023
| Revenue | NOK 116,2M | +5% |
| EBITDA | NOK 2,1M | -32% |
| Net profit | NOK 2,3M | -14% |
| Total assets | NOK 54,3M | +16% |
| Equity | NOK 33,4M | +7% |
| Employees | 12 | — |
Legal name
FISHER SCIENTIFIC AS
Org number
940354137
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4. juni 1986
Share capital
NOK 400 000
Employees
12 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder alene.
Address
Ullernchausséen 52, 0379 Oslo
Phone
+4722955940
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 73 533 | 92 276 | 102 679 | 110 679 | 116 165 |
| Staff expenses | −1 648 | −1 920 | −1 865 | −0 | −0 |
| EBITDA | 1 801 | 3 217 | 2 825 | 3 130 | 2 125 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 1 801 | 3 217 | 2 825 | 3 130 | 2 125 |
| Net financials | −811 | 85 | −0 | 263 | 820 |
| Profit before tax | 990 | 3 302 | 2 825 | 3 393 | 2 945 |
| Tax | −0 | −0 | −6 939 | −0 | −0 |
| Net profit | 990 | 3 302 | 9 765 | 2 627 | 2 252 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 27 252 | 35 044 | 49 773 | 46 911 | 54 277 |
| Equity | 15 474 | 18 776 | 28 540 | 31 167 | 33 419 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 11 778 | 16 268 | 21 232 | 15 744 | 20 857 |
| Total debt | 11 778 | 16 268 | 21 232 | 15 744 | 20 857 |
EBITDA margin
1.8%
This company
15.8%
Market median
-89% vs market
20202024
Equity ratio
61.6%
This company
38.2%
Market median
+61% vs market
20202024
Return on equity
6.7%
This company
18.4%
Market median
-64% vs market
20202024
Net profit margin
1.9%
This company
8.1%
Market median
-77% vs market
20202024
Asset turnover
2.14×
This company
1.12×
Market median
+91% vs market
20202024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2022 | |
| Board of Directors | 2026 | |
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Former (3) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2019 – 2022 | |
| Board of Directors | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fisher Scientific Norway As
FISHER SCIENTIFIC AS Board members of FISHER SCIENTIFIC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Petrus Thomas Adrianus Van Der Zande | Chairman | 0 companies |
| Thomas Arthur Nicholson | Board of Directors | 0 companies |
| Arabella Lucy Mary Von Habsburg Lothringen | Board of Directors | 0 companies |
| Carolin Sonja Freidel | Board of Directors | 0 companies |
| Jørgen Viktil | Board of Directors | 0 companies |
| Kari Johanne Jørgensen | Board of Directors | 0 companies |
| Anne Omholt | Board of Directors | 0 companies |